Policy shift on generic drugs

What is the issue?

\n\n

\n
- Earlier government made a decision that all doctors will have to prescribe medicines using their generic or chemical names.
\n
- Now there is a policy shift that doctors cannot be banned from prescribing the brand names of the generic drugs.
\n

\n\n

What are generic drugs?

\n\n

\n
- A brand-name drug product is originally discovered and developed by a pharmaceutical company.
\n
- It is estimated that bringing a new drug to market costs the innovator on average $802 million over a period of 10 to 15 years.
\n
- So a patent allows the innovator to sell the branded drug exclusively in order to recoup money spent during development and to generate a profit.
\n
- Generics are off-patent, less-expensive drugs that are chemically similar to an innovative drug.
\n

\n\n

What are the reasons for the shift?

\n\n

\n

- There is a contradiction in asking doctors to prescribe generics when the market is full of branded drugs.
  \n
- There is a lack of confidence in the quality of medicines being dispensed.
  \n
- Writing out all the key ingredients while prescribing even a simple medicine can be difficult.
  \n
- If the chemist does not understand the prescription, it creates more problems.
  \n
- Pharmacists in chemist shops will gain more power to decide which brand of generic drug is to be given to a patient.
  \n

\n\n

How can the issues be addressed?

\n\n

  \n
- Patients in developed countries get their medicines from a well-developed healthcare system and not the retail market.
  \n
- Investment in the drug regulatory and testing infrastructure to ensure that quality drugs.
  \n
- Companies are supported to meet GMP (Good Manufacturing Practices) norms.
  \n
- Only then will consumers and doctors have confidence that a medicine picked up anywhere in the country is of a good quality.
  \n

\n\n

\n\n

Source: Business Line

\n

IAS PARLIAMENT

Information is Empowering

A Shankar IAS Academy Initiative